Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2011 Feb;26(2):584-91.
doi: 10.1093/ndt/gfq419. Epub 2010 Jul 14.

Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease

Tamara Isakova  1 , Orlando M Gutiérrez, Kelsey Smith, Michael Epstein, Leigh K Keating, Harald Jüppner, Myles Wolf
Affiliations
Randomized Controlled Trial

Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease

Tamara Isakova et al. Nephrol Dial Transplant. 2011 Feb.

Abstract

Background: High levels of fibroblast growth factor 23 (FGF23) are associated with mortality and progression of chronic kidney disease (CKD). Reducing dietary phosphorus intake lowers FGF23 secretion in healthly individuals, but there is little data on its effects in patients with pre-dialysis CKD.

Methods: Using a 2×2 factorial design, we randomly assigned 16 normophosphataemic CKD stage 3-4 patients to receive a 2-week treatment with either lanthanum carbonate 1000 mg three times daily or placebo, and to ingest a tightly controlled diet containing 750 or 1500 mg of dietary phosphorus daily. We analysed serial measurements of FGF23, parathyroid hormone, serum phosphate and calcium, and 24-h urinary phosphate and calcium excretion using repeated-measures analyses.

Results: Compared with the 1500-mg phosphorus diet, patients assigned to the 750-mg diet had greater reduction in 24-h urinary phosphate excretion (66% vs. 29%; P<0.0001). Lanthanum-treated patients experienced a significant reduction in 24-h urinary phosphate excretion compared with baseline (64%; P<0.0001), but the difference compared with placebo did not reach significance (64% vs. 31%). Despite the significant reductions in 24-h urinary phosphate excretion, no group demonstrated a significant reduction in FGF23 levels; FGF23 levels actually increased significantly in the 1500-mg diet plus placebo group, suggesting dietary phosphorus loading.

Conclusions: Although dietary phosphorus restriction and lanthanum lowered urinary phosphate excretion consistent with a rapid decrease in phosphorus absorption, inducing a reduction in FGF23 levels in CKD patients may require interventions with a longer duration than in healthy volunteers.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Mean absolute (A) and percent change from baseline (B) in 24-h urinary phosphate excretion during the 2-week intervention period. Error bars represent standard errors.
Fig. 2
Fig. 2
Mean 24-h urinary phosphate excretion (A), serum phosphate (B), cFGF23 (C) and iPTH (D) in participants assigned to 750-mg (n = 8) versus 1500-mg phosphorus diet (n = 8). Error bars represent standard errors.
Fig. 3
Fig. 3
Mean 24-h urinary phosphate excretion (A), serum phosphate (B), cFGF23 (C) and iPTH (D) in participants assigned to lanthanum carbonate (n = 8) versus placebo (n = 8). Error bars represent standard errors.
Fig. 4
Fig. 4
Mean percent change from baseline in cFGF23 levels during the 2-week intervention period. Error bars represent standard errors.
See this image and copyright information in PMC

Comment in

References

    1. Saito H, Kusano K, Kinosaki M, et al. Human fibroblast growth factor-23 mutants suppress Na+-dependent phosphate co-transport activity and 1alpha, 25-dihydroxyvitamin D3 production. J Biol Chem. 2003;278:2206–2211. - PubMed
    1. Shimada T, Hasegawa H, Yamazaki Y, et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res. 2004;19:429–435. - PubMed
    1. Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V, et al. The parathyroid is a target organ for FGF23 in rats. J Clin Invest. 2007;117:4003–4008. - PMC - PubMed
    1. Gutierrez O, Isakova T, Rhee E, et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol. 2005;16:2205–2215. - PubMed
    1. Larsson T, Nisbeth U, Ljunggren O, et al. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int. 2003;64:2272–2279. - PubMed

Publication types